Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin.
Study Goal
The researchers aimed to determine whether a prudent diet combined with cholestyramine could reduce coronary atherosclerosis progression in men with familial hypercholesterolaemia (FH).
Results Summary
The study found that the diet plus cholestyramine significantly reduced LDL cholesterol by 35% and slowed coronary atherosclerosis progression compared to usual care, with fewer patients showing progression and some showing regression.
Population
26 men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD).
Effective Dosage
Cholestyramine 8 g twice daily (diet details not specified).
Duration
39 months.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
fat-modified diet plus cholestyramine (8 g twice daily) | decrease | coronary atherosclerosis | men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD) | - | decrease | #1 |
fat-modified diet plus cholestyramine (8 g twice daily) | decrease | mean plasma LDL-Ch concentration | men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD) | 35% | fell | #2 |
fat-modified diet plus cholestyramine (8 g twice daily) | decrease | mean plasma LDL-Ch concentration | men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD) | 3.78 (SD 0.98) mmol/L compared with UC at 4.89 (1.04) | remained significantly lower | #3 |
usual care | decrease | MAWS (mean absolute width of segments) | men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD) | 0.252 (SEM 0.072) mm | decreased | #4 |
fat-modified diet plus cholestyramine (8 g twice daily) | decrease | MAWS (mean absolute width of segments) | men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD) | 0.001 (0.065) mm | decreased | #5 |
usual care | decrease | MinAWS (minimum absolute width of segments) | men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD) | 0.290 (0.087) mm | reductions | #6 |
fat-modified diet plus cholestyramine (8 g twice daily) | decrease | MinAWS (minimum absolute width of segments) | men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD) | 0.013 (0.058) mm | reductions | #7 |
usual care | increase | coronary atherosclerosis | men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD) | 7 patients (50%) | progression was observed | #8 |
fat-modified diet plus cholestyramine (8 g twice daily) | increase | coronary atherosclerosis | men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD) | 3 patients (25%) | progression was observed | #9 |
usual care | decrease | coronary atherosclerosis | men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD) | no patients (0%) | regression | #10 |
fat-modified diet plus cholestyramine (8 g twice daily) | decrease | coronary atherosclerosis | men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD) | 3 patients (25%) | regression | #11 |
prudent diet and cholestyramine | increase | course of coronary atherosclerosis | men with phenotypic FH | - | improve | #12 |
prudent diet and cholestyramine | decrease | LDL-Ch | men with phenotypic FH | - | sustained reductions | #13 |
BACKGROUND AND AIMS: Familial hypercholesterolaemia (FH) profoundly increases the risk of coronary artery disease (CAD). We investigated whether diet and a bile-acid sequestrant decrease coronary atherosclerosis in patients with FH. METHODS: We identified 26 men with FH and CAD, participating in the St Thomas' Atherosclerosis Regression Study, who had been randomized to receive a fat-modified diet plus cholestyramine (8 g twice daily) (DC, n = 12) or usual care (UC, n = 14), and investigated the relative effects of these treatments on the angiographic progression of coronary atherosclerosis over 39 months. FH was defined as probable/definite according to Dutch Lipid Clinic Network criteria; mean FH score was 8.7 (range 6-15) and mean baseline low-density lipoprotein cholesterol (LDL-Ch) concentration was 5.4 (SD 1.4) mmol/L. Coronary atherosclerosis was assessed by serial quantitative angiography as the global changes in mean and minimum absolute width of segments (MAWS and MinAWS, respectively). RESULTS: Mean plasma LDL-Ch concentration fell by 35% with DC and remained significantly (p < 0.001) lower during the trial at 3.78 (SD 0.98) mmol/L compared with UC at 4.89 (1.04). MAWS decreased by 0.252 (SEM 0.072) mm in the UC group and by 0.001 (0.065) mm in the DC group (p = 0.007), with corresponding reductions in MinAWS of 0.290 (0.087) mm and 0.013 (0.058) mm (p = 0.009); these changes were significant after adjusting for baseline variables, including coronary luminal dimensions and lipoprotein(a). Progression was observed in 7 patients (50%) on UC and 3 (25%) on DC (p = 0.19), with regression in no patients (0%) and 3 patients (25%) (p < 0.05), respectively. CONCLUSIONS: This investigation, carried out in the pre-statin era, demonstrates that a prudent diet and cholestyramine could improve the course of coronary atherosclerosis in men with phenotypic FH through sustained reductions in LDL-Ch.